Sareum Share Discussion Threads

[barkbooo] 15/6/2022 08:31

Norm - every single person involved in stopping that flight should be named. We are the ones that will have to cover the cost of the illegal immigrants.

The majority of the good people in our country have had enough.

So an ECHR judge has ruled that people braking the law - entering our country with the aid of gangsters and from the safety of France, cannot be flown to Rwanda to have thier application processed.

The highest court in our land has ruled this Rwanda process to be legal - common sense really...

My suggestion now - every single person involved in this attempt to destabilise our country, should be named and shamed. From Strasbourg to Swindon from Brussels to Birmingham - we want their names and addresses, we want to research their background, we want to see how peaceful their living arrangements are, and more importantly..we want to know their financial interest!

If this Government and its voters do not fight back now - we have no future!!

[criticalthinker1] 14/6/2022 22:54

So it the patent was granted...

"We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones."
The board have been silent albeit squeaky chairs in Q and A :-)
Mr Reader has taken another position. Fair play! Intriguing recent tweets with reference to DDR et al.
Henry fwiw if you respond you are just like an unwanted relative you had to invite to a family party and unfortunately they turned up. But you corner the 80 year old auntie and tell her your woes and how you are misunderstood....but auntie I am right...they just don't understand...I mean you understand I'm right and if I get a genuine point that contradicts me then that's naughty! Lmao
Fireworks incoming. Love hugs kisses big yachts wotsits Brent....et al.
CT or am I Steadydanny woooooo!!
All best to genuine holders. Its occurring. Booom

[criticalthinker1] 14/6/2022 22:28

If people are having trouble joining the dots then this from July 21
US Patent Notice of Allowance for Sareum's SDC-1802

Cambridge, UK, 30 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme").

The patent (US Patent Application no. 16/343,639) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.

The Company expects that the patent will be granted within three months, subject to certain formalities being completed

Please read the first paragraph slowly. Pound to a penny its Kowalski at SO when he was possibly there utilising 1802 (very similar to 1801) with AZD5153 or SRA737
or momo.... and hence the US Patent.
So we have 1801 going to CTA and 1802 as a side order being used as A Notice of Allowance as an invention associated with our proprietary 1802!!!
And we have 1801 oven ready for CTA and tox approved which has HNWI backing which 1802 benefits from any of our research. Win win!
Anyone think we have the golden carrot that we have in front of GSK et al and we are on the cusp of something extraordinary!? I think our board are going to be billionaires!
Regards CT.

[horridhenry] 14/6/2022 15:58

i notice that there is a member of the knuckle draggers questioning why anyone would sell ??

[silvergreyhead1] 14/6/2022 13:38

No way HH surely it's the share price being manipulated down to let the MMs mates in just before the big news which is coming tomorrow or the day after or well soonish.That's what's being said elsewhere anyway.

[horridhenry] 14/6/2022 11:55

for anyone thinking market makers are manipulating the share price downward, you are wrong. There is a largish seller and the MM's are feeding it into the market in chunks, and the share price has dropped in order to attract buyers to sell the stock they have purchased

Easy isn't it ?

[horridhenry] 14/6/2022 09:01

the activity on twitter seems to be increasing.

[horridhenry] 14/6/2022 08:49

The CTA is priced in steadydanny (known liar)

[kwizza] 14/6/2022 08:21

Posted on the Sareum twitter page

[criticalthinker1] 13/6/2022 19:24

Oh and this Henry re autoimmune...
Cambridge, UK, 16 March 2022 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, is pleased to provide an update on the development of its proprietary TYK2/JAK1 inhibitor SDC-1801 towards first-in-human trials. As disclosed in the Company’s half-year results on 21 February 2022, the data analysis from the preclinical toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation (“CTA”) is complete. The Company has now received the final signed report from the Contract Research Organisation that conducted these studies and, as previously reported, these data fully support the Company’s plan to submit a CTA application in mid-2022 and to commence a Phase 1a clinical trial with SDC-1801 in H2 2022.

SDC-1801 is being developed as a potential new treatment for a range of autoimmune diseases and for the acute respiratory symptoms of Covid-19.

The report confirms that the studies met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining an appropriate dose range to test in first-in-human studies.
I'm reckoning a RNS is about to fly in here re CTA. Or is it going to be trumped by a license agreement?
Tyk tok CT1

[criticalthinker1] 13/6/2022 17:42

Henry just to enlighten you...take note of last part..

There’s about a 70% overlap in customer base between momelotinib, Blenrep and other hematology products, said Luke Miels, chief commercial officer at GSK.

Last year, GSK’s oncology business accounted for approximately 2.8% of total pharmaceutical sales.

Momelotinib, which Sierra acquired from Gilead Sciences in 2018 for US$198 million including milestone payments, could generate US$950 million in peak sales in the US and US$780 million in peak sales outside the US, according to HC Wainwright’s Joseph Pantginis in a late January analyst note.

GSK has had several trial setbacks in the last year with cancer compounds bintrafusp alfa and feladilimab, which were previously touted as potential billion-dollar sellers.

It will lose patent exclusivity on the HIV drug dolutegravir, which is worth approximately £3 billion (US$3.9 billion) in annual sales, at the end of 2027.

GSK agreed in June to pay iTeos Therapeutics Inc up to US$2 billion to collaborate on the development and commercialization of a potential cancer treatment.

Miels signaled GSK continues to have an appetite for deals like Sierra. “They could be anywhere ranging from cancer, anti-infectives, vaccines, renal, autoimmune,” he said.
Now reply with a valid/individual point rather than sponging off other posters. Go on give it a try.

[criticalthinker1] 13/6/2022 14:31

RNS August 21
Sareum's CEO, Dr Tim Mitchell, commented:

"It is encouraging to note from Sierra's investor call that, while it has made no commitment towards the further development of SRA737, it sees further potential opportunities for this novel agent following the addition of AZD5153 into its pipeline. We remain optimistic that Sierra will find a solution to advance development of the SRA737 programme in the future."
I'm of the opinion that the addition of AZD5153 into SO pipeline is on GSKs radar. Kowalski was mentioned by our board and they were excited by his appointment and mention of 737. I believe he has moved on but momo was already in full flow. I believe in the background he has put together tangible worth/intrigue to SO pipeline and GSK are rather interested in 737 and 5153.Its not all about momo imo but hopefully news in a mo when/if the deal occurs. I think it will.

[silvergreyhead1] 13/6/2022 12:21

I honestly can't go along with 737 being the real target theories. However the post on LSE last week from WIP re his visit to Brentford and seeing what he saw?. That's quite intriguing whatever he saw satisfies him his investment is right and he was adding more.Being honest I hope they do have an understanding of 737 and have a plan for it hopefully it's not going to stay on the shelf for months again.Who knows just wish they would get a move on and sell up a billion would be nice, two has become a faraway dream from now on I think.

[silvergreyhead1] 11/6/2022 16:27

Well guess I can't be as I had to Google who the f.ck they are.Like the fact they had a Northumberland clan though.

[barkbooo] 11/6/2022 08:42

Silver - you are not part of the reborn Brigantes, are you?

I like my Yorkshire tea with nowt taken out - we are all mates today!

[barkbooo] 11/6/2022 08:19

Silver - there is also a thoroughbred named klipperty klopp..a six year old bay gelding owned and trained by Anthony Brittain.
So on the plus side - he is castrated, there will be no more klipperty klopps.
On a more serious note - Klopp is a breath of fresh air, a proven great manager, a humble guy and a human being that radiates the fun and excitement of premier league football..and that’s praise coming from a hammers supporter.